{
    "clinical_study": {
        "@rank": "43469", 
        "arm_group": [
            {
                "arm_group_label": "NaCl 3% inhalations + standard therapy", 
                "arm_group_type": "Active Comparator", 
                "description": "In this group, patients receive NaCl 3% inhalations ( 4ml QID) together with standard therapy.\nStandard therapy includes suctioning nasal secretions, water-electrolyte balance maintenance and oxygen supplementation when needed."
            }, 
            {
                "arm_group_label": "Standard therapy", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Standard therapy includes suctioning nasal secretions, water-electrolyte balance maintenance and oxygen supplementation when needed"
            }
        ], 
        "brief_summary": {
            "textblock": "Our study will investigate inhalation therapy of NaCl 3% compared to standard therapy with\n      no inhalation in the treatment of moderate to severe bronchiolitis. The impact on length of\n      hospital stay will be analyzed."
        }, 
        "brief_title": "Moderate to Severe Bronchiolitis: Standard Therapy Versus Therapy With NaCl 3% Inhalations", 
        "completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Moderate to Severe Bronchiolitis", 
        "condition_browse": {
            "mesh_term": "Bronchiolitis"
        }, 
        "detailed_description": {
            "textblock": "Acute viral bronchiolitis is the most common lower respiratory tract infection in the first\n      year of life and leads to a large number of hospital admissions. The only recommended\n      treatment is supportive. However many different types of drug inhalations have been studied\n      but their efficacy remains controversial.\n\n      Our study will compare recommended supportive therapy to supportive therapy combined to\n      hypertonic saline (NaCl 3%) inhalations in the treatment of moderate to severe\n      bronchiolitis. This will be the first study to use a true control group with no inhalation."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  children between ages 6 weeks to 24 months\n\n          -  first episode of wheezing\n\n          -  diagnosis of moderate to severe bronchiolitis: The patients are ranked as moderately\n             to severely ill according to the Wang clinical severity score\n\n        Exclusion Criteria:\n\n          -  Children with mild bronchiolitis (Wang score < 5)\n\n          -  Children with pre-existent cardiac disease\n\n          -  Children with clinically significant chronic respiratory disease\n\n          -  Immunocompromised children\n\n          -  Children with a gestational age at birth less than 34 weeks\n\n          -  Children who received immunoprophylaxis therapy (i.e RSV immune globulin therapy)\n\n          -  Children who received corticosteroid in any form in the preceding 2 weeks before\n             presentation\n\n          -  Children who received bronchodilators within 24 hours before presentation\n\n          -  Children with critical illness at presentation requiring immediate admission to\n             intensive care unit"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "24 Months", 
            "minimum_age": "6 Weeks"
        }, 
        "enrollment": {
            "#text": "120", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 14, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01812525", 
            "org_study_id": "453/12"
        }, 
        "intervention": [
            {
                "arm_group_label": "NaCl 3% inhalations + standard therapy", 
                "description": "NaCl 3%: 4ml QID", 
                "intervention_name": "NaCl 3%", 
                "intervention_type": "Drug", 
                "other_name": "Mucoclear 3%"
            }, 
            {
                "arm_group_label": [
                    "NaCl 3% inhalations + standard therapy", 
                    "Standard therapy"
                ], 
                "description": "Standard therapy includes suctioning nasal secretions, water-electrolyte balance maintenance and oxygen supplementation when needed", 
                "intervention_name": "Standard therapy", 
                "intervention_type": "Other"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Bronchiolitis", 
            "Moderate to Severe", 
            "Hypertonic saline", 
            "NaCl 3% inhalations", 
            "Standard therapy", 
            "Wang score", 
            "in-patients"
        ], 
        "lastchanged_date": "April 16, 2013", 
        "location": {
            "contact": {
                "email": "rpilloud@hotmail.com", 
                "last_name": "Raphaelle A Jaquet-Pilloud, MD"
            }, 
            "contact_backup": {
                "email": "jean-yves.pauchard@chuv.ch", 
                "last_name": "Jean-Yves Pauchard, MD"
            }, 
            "facility": {
                "address": {
                    "city": "Lausanne", 
                    "country": "Switzerland", 
                    "state": "Vaud", 
                    "zip": "1000"
                }, 
                "name": "H\u00f4pital de l'Enfance"
            }, 
            "investigator": [
                {
                    "last_name": "Raphaelle A Jaquet-Pilloud, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Jean-Yves Pauchard, MD", 
                    "role": "Principal Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Switzerland"
        }, 
        "number_of_arms": "2", 
        "official_title": "Moderate to Severe Bronchiolitis: Standard Therapy Versus Therapy With NaCl 3%", 
        "overall_contact": {
            "email": "raphaelle.pilloud@chuv.ch", 
            "last_name": "Raphaelle Aurelia Jaquet-Pilloud, MD", 
            "phone": "004179 556 6264"
        }, 
        "overall_contact_backup": {
            "email": "jean-yves.pauchard@chuv.ch", 
            "last_name": "Jean-Yves Pauchard, MD", 
            "phone": "004179 556 2816"
        }, 
        "overall_official": {
            "affiliation": "H\u00f4pital de l'Enfance, Lausanne, Switzerland", 
            "last_name": "Jean-Yves Pauchard", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Switzerland: Swissmedic", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The length of stay is defined as the time between study entry and the time at which the child reach protocol-defined discharge criteria as measured by the physician in charge.", 
            "measure": "length of hospital stay", 
            "safety_issue": "No", 
            "time_frame": "2 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01812525"
        }, 
        "responsible_party": {
            "investigator_affiliation": "H\u00f4pital de L'Enfance", 
            "investigator_full_name": "Raphaelle Jaquet-Pilloud", 
            "investigator_title": "Jean-Yves Pauchard, MD", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "transfer rate to ICU", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "measure": "readmission rate in the next 7 days following discharge", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "measure": "Wang clinical severity score evolution", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "measure": "adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "2 years"
            }, 
            {
                "measure": "Patients' ability to feed", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }
        ], 
        "source": "H\u00f4pital de L'Enfance", 
        "sponsors": {
            "collaborator": {
                "agency": "Swiss foundation for the health of children and adolescents, Pfizer AG, Z\u00fcrich", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Raphaelle Jaquet-Pilloud", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2013"
    }
}